/
Neurology
Cognitive Impairment
53
Pipeline Programs↗
118
Active Trials↗
67
Companies Involved↗
Cognitive impairment is a moderately active landscape with 53 programs across 67 companies. The most active players are Takeda, CereMark Pharma, LLC, Qilu Pharmaceutical Co., Ltd.. 10 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical22
Phase 18
Phase 213
Phase 310
Approved
No programs
Analysis
Modality Breakdown
88%
Small molecule
43 of 49 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 49 classified programs, each share of the total. Modality classified for 94% of 53 pipeline programs.
Analysis
Trial Status
366
clinical trials
Completed161 · 44%
Recruiting67 · 18%
Terminated36 · 10%
Unknown status34 · 9%
Not yet recruiting27 · 7%
Active, not recruiting21 · 6%
Other20 · 5%
Clinical Trials
Trial Activity
366 trials
Olfactory Training in Mild Cognitive Impairment
Recruiting·—·Preclinical·NCT06825403·30 enrolled
Page 1 of 25
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)